ADMA Biologics (ADMA)
Market Price (1/16/2026): $17.4 | Market Cap: $4.2 BilSector: Health Care | Industry: Biotechnology
ADMA Biologics (ADMA)
Market Price (1/16/2026): $17.4Market Cap: $4.2 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.1% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 25x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 64x |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 34% | Key risksADMA key risks include [1] its history of substantial operating losses and a $506.3 million accumulated deficit, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13% | |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Plasma-Derived Therapies, Targeted Therapies, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.1% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 34% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Plasma-Derived Therapies, Targeted Therapies, Show more. |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 25x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 64x |
| Key risksADMA key risks include [1] its history of substantial operating losses and a $506.3 million accumulated deficit, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
ADMA Biologics reported robust financial performance for the third quarter of 2025, with total revenue reaching $134.2 million, marking a 10% sequential and 12% year-over-year increase. The company also achieved a GAAP net income of $36.4 million and an adjusted EBITDA of $58.7 million. Following these results, management raised its full-year 2025 revenue guidance to $510 million (from over $500 million) and its 2026 revenue guidance to at least $630 million.
2. Positive Preliminary Full Year 2025 Revenue and Strong 2026/2027 Outlook.
On January 12, 2026, ADMA announced preliminary unaudited total revenues for full-year 2025 between $510 million and $511 million, meeting or surpassing its prior guidance. The company further upgraded its 2026 revenue outlook to approximately $635 million and its adjusted EBITDA guidance for 2026 to around $360 million. Additionally, ADMA provided initial 2027 guidance, projecting revenues of approximately $775 million, adjusted net income of $315 million, and adjusted EBITDA of $455 million.
3. Strategic Plasma Network Repositioning and Enhanced Supply Visibility.
In December 2025, ADMA Biologics completed the divestiture of three plasma collection centers for $12 million. Concurrently, the company established long-term plasma supply agreements with the buyer and expanded its relationships with third-party suppliers, now accessing over 280 plasma collection centers. This strategic move is anticipated to improve long-term supply visibility through the late 2030s and is expected to generate accretive cost savings beginning in 2026.
4. Successful Commercial-Scale Implementation of Yield-Enhanced Production.
ADMA successfully implemented its yield-enhanced production at a commercial scale during 2025. This operational improvement is expected to be a significant driver for margin expansion, with 2026 projected as the first full year of monetizing these higher-yield batches. This efficiency gain allows the company to produce more product from the same plasma input, directly boosting profitability.
5. Accelerating Demand for ASCENIV and Expanded Distribution.
The company reported accelerating demand for its lead product, ASCENIV, driven by record utilization and expanding prescriber adoption, with clear visibility into sustained demand growth throughout 2026. To further support this growth, ADMA signed a new authorized distribution agreement with McKesson Specialty in the fourth quarter of 2025 for both ASCENIV and BIVIGAM, which is expected to broaden access to additional sites of care and patient populations. Show more
Stock Movement Drivers
Fundamental Drivers
The 12.4% change in ADMA stock from 10/31/2025 to 1/16/2026 was primarily driven by a 10.8% change in the company's P/E Multiple.| 10312025 | 1162026 | Change | |
|---|---|---|---|
| Stock Price ($) | 15.48 | 17.40 | 12.40% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 474.17 | 488.56 | 3.03% |
| Net Income Margin (%) | 44.06% | 42.87% | -2.70% |
| P/E Multiple | 17.89 | 19.82 | 10.78% |
| Shares Outstanding (Mil) | 241.49 | 238.60 | 1.20% |
| Cumulative Contribution | 12.39% |
Market Drivers
10/31/2025 to 1/16/2026| Return | Correlation | |
|---|---|---|
| ADMA | 11.8% | |
| Market (SPY) | 1.4% | 47.8% |
| Sector (XLV) | 8.0% | 50.4% |
Fundamental Drivers
The -7.0% change in ADMA stock from 7/31/2025 to 1/16/2026 was primarily driven by a -7.8% change in the company's P/E Multiple.| 7312025 | 1162026 | Change | |
|---|---|---|---|
| Stock Price ($) | 18.70 | 17.40 | -6.95% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 459.38 | 488.56 | 6.35% |
| Net Income Margin (%) | 45.01% | 42.87% | -4.76% |
| P/E Multiple | 21.50 | 19.82 | -7.82% |
| Shares Outstanding (Mil) | 237.78 | 238.60 | -0.35% |
| Cumulative Contribution | -6.95% |
Market Drivers
7/31/2025 to 1/16/2026| Return | Correlation | |
|---|---|---|
| ADMA | -7.4% | |
| Market (SPY) | 9.7% | 34.2% |
| Sector (XLV) | 20.0% | 49.5% |
Fundamental Drivers
The 7.7% change in ADMA stock from 1/31/2025 to 1/16/2026 was primarily driven by a 140.9% change in the company's Net Income Margin (%).| 1312025 | 1162026 | Change | |
|---|---|---|---|
| Stock Price ($) | 16.15 | 17.40 | 7.74% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 382.81 | 488.56 | 27.62% |
| Net Income Margin (%) | 17.80% | 42.87% | 140.87% |
| P/E Multiple | 55.60 | 19.82 | -64.35% |
| Shares Outstanding (Mil) | 234.57 | 238.60 | -1.72% |
| Cumulative Contribution | 7.71% |
Market Drivers
1/31/2025 to 1/16/2026| Return | Correlation | |
|---|---|---|
| ADMA | 7.2% | |
| Market (SPY) | 15.9% | 43.5% |
| Sector (XLV) | 7.4% | 45.7% |
Fundamental Drivers
The 371.5% change in ADMA stock from 1/31/2023 to 1/16/2026 was primarily driven by a 274.4% change in the company's Total Revenues ($ Mil).| 1312023 | 1162026 | Change | |
|---|---|---|---|
| Stock Price ($) | 3.69 | 17.40 | 371.54% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 130.48 | 488.56 | 274.43% |
| P/S Multiple | 5.55 | 8.50 | 53.01% |
| Shares Outstanding (Mil) | 196.38 | 238.60 | -21.50% |
| Cumulative Contribution | 349.75% |
Market Drivers
1/31/2023 to 1/16/2026| Return | Correlation | |
|---|---|---|
| ADMA | 369.1% | |
| Market (SPY) | 76.5% | 35.1% |
| Sector (XLV) | 22.2% | 33.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ADMA Return | -28% | 175% | 16% | 279% | 6% | -4% | 797% |
| Peers Return | 5% | -38% | -23% | 159% | 9% | 2% | 42% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 85% |
Monthly Win Rates [3] | |||||||
| ADMA Win Rate | 50% | 83% | 42% | 75% | 50% | 0% | |
| Peers Win Rate | 50% | 38% | 38% | 62% | 54% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| ADMA Max Drawdown | -44% | -9% | -22% | -3% | -18% | -4% | |
| Peers Max Drawdown | -35% | -44% | -49% | -21% | -37% | -6% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | 0% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CSL, EBS. See ADMA Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/16/2026 (YTD)
How Low Can It Go
| Event | ADMA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -63.1% | -25.4% |
| % Gain to Breakeven | 170.6% | 34.1% |
| Time to Breakeven | 395 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -67.3% | -33.9% |
| % Gain to Breakeven | 206.0% | 51.3% |
| Time to Breakeven | 1,244 days | 148 days |
| 2018 Correction | ||
| % Loss | -68.3% | -19.8% |
| % Gain to Breakeven | 215.7% | 24.7% |
| Time to Breakeven | 1,958 days | 120 days |
Compare to CSL, EBS
In The Past
ADMA Biologics's stock fell -63.1% during the 2022 Inflation Shock from a high on 2/9/2021. A -63.1% loss requires a 170.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-2 brief analogies to describe ADMA Biologics:
- A smaller, specialized Grifols, focusing on plasma-derived therapies like IVIG.
- An integrated biopharmaceutical company that develops and manufactures plasma-derived medicines, similar to a specialized division of CSL Behring.
AI Analysis | Feedback
- BIVIGAM®: An immune globulin intravenous (human) used to treat primary humoral immunodeficiency (PI) in adults and pediatric patients.
- ASCENIV™: An immune globulin intravenous (human, liquid) indicated for the treatment of primary humoral immunodeficiency (PI) in adults and pediatric patients aged 12 years and older.
- NABI-HB®: A hepatitis B immune globulin (human) used for immediate and long-term protection against hepatitis B virus infection.
AI Analysis | Feedback
ADMA Biologics (ADMA) sells primarily to other companies, not directly to individuals.
ADMA's sales and distribution strategy involves marketing its specialized plasma-derived biologics (such as BIVIGAM, ASCENIV, and NABI-HB) through a direct sales force in the United States. Its direct customers, which facilitate the distribution and administration of its products to end-users, include:
- Wholesale drug distributors
- Specialty pharmacies
- Hospitals
- Alternate treatment sites (e.g., infusion centers)
- Physician offices
- Group Purchasing Organizations (GPOs)
Regarding its major customers, ADMA's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, states that the company depends on a limited number of specialty distributors and wholesale customers. The report indicates that two customers individually represented more than 10% of ADMA's total net product sales, accounting for approximately 42% and 15% of net product sales, respectively, for that year. However, ADMA Biologics does not explicitly name these specific customer companies in its public filings.
AI Analysis | Feedback
BPL Plasma Inc.
AI Analysis | Feedback
Adam S. Grossman, Founder, Director, President, & Chief Executive Officer
Mr. Grossman founded ADMA Biologics in 2007 and has served as President and Chief Executive Officer since October 2011. He was previously Executive Vice President of National Hospital Specialties and GenesisBPS from 1994 to 2011. GenesisBPS, a medical device firm, was acquired in September 2025. Mr. Grossman led ADMA's public offering in 2013 and has completed over $1.2 billion in equity capital markets financing and debt transactions. He also led the asset acquisition of the Biotest Therapy Business Unit in 2017. His career also includes roles at MedImmune, Inc. and the American Red Cross. He is the son of co-founder Dr. Jerrold B. Grossman.
Brad L. Tade, Chief Financial Officer & Treasurer
Mr. Tade joined ADMA Biologics in June 2023 as Vice President of Financial Operations and was appointed Chief Financial Officer & Treasurer. He brings over 20 years of experience in the medical device industry. Prior to ADMA, he served as Vice President of Finance for Commercial Packaging Technology and Development and Manufacturing at PCI Pharma Services, and previously held Vice President of Finance roles at Baxter and Becton Dickinson.
Kaitlin Kestenberg, Chief Operating Officer & Senior Vice President, Compliance
Ms. Kestenberg has been the Chief Operating Officer and Senior Vice President, Compliance of ADMA Biologics since April 2024. Her background includes quality and operational leadership positions at Merck, Charles River Laboratories, BioReliance, and ElevateBio.
Jerrold B. Grossman, D.P.S., Founder & Vice Chairman
Dr. Grossman is a co-founder of ADMA Biologics in 2007 and has over 35 years of experience in the blood and plasma industry. He is the founder and CEO of Technomed, Inc. (formerly National Hospital Specialties) since 1980, and was the founder and President of GenesisBPS from 1990 until its acquisition in September 2025. Dr. Grossman was also a founder and former director of Pascack Bancorp, Inc., which was acquired by Lakeland Bancorp, Inc. in January 2016.
Steven A. Elms, Chairman
Mr. Elms has served as a director of ADMA Biologics since 2007 and is the company's Chairman of the Board. He is a Managing Partner at Aisling Capital, a life sciences-focused private equity firm, which he joined in 2000. Previously, he was a Principal in the Life Sciences Investment Banking Group of Hambrecht & Quist, where he was involved in over 60 financing and merger and acquisition transactions. Mr. Elms also serves on the board of directors for other companies, including Elevation Oncology and Marker Therapeutics.
AI Analysis | Feedback
ADMA Biologics (ADMA) faces several key risks to its business operations, primarily centered around its financial stability, regulatory compliance, and production capabilities. The most significant risk category for ADMA Biologics is **Finance & Corporate**, accounting for 32% of identified risks. The company has a history of operating losses, incurring net losses of $71.6 million in 2021, $65.9 million in 2022, and $28.2 million in 2023, resulting in an accumulated deficit of $506.3 million through December 31, 2023. While ADMA Biologics generated positive cash flow from operations in 2023, it had consumed substantial amounts of cash since its inception, with negative cash flows from operations in 2021 and 2022. There is also a risk that the company may not achieve profitability in 2024 and beyond. Furthermore, the liquidity of ADMA's securities could be impaired, and there's a risk of delisting from the Nasdaq Global Market if it fails to adhere to strict listing requirements. A substantial risk also stems from **Legal & Regulatory** factors, representing 26% of the company's risk profile. As a biopharmaceutical company, ADMA Biologics is subject to rigorous regulatory oversight, and changes in regulations or difficulties in maintaining compliance could impact its stock value and operations. **Production Risks** constitute 21% of the identified risks. The manufacturing process for biologics, such as immune globulin (IG), is inherently complex and time-consuming, typically taking 7 to 12 months from collection to release. This complexity means that challenges related to manufacturing efficiency, quality control (cGMP), and potential supply chain disruptions, including those influenced by geopolitical conditions, could materially affect the business.AI Analysis | Feedback
The emergence of curative gene therapies for specific types of primary immunodeficiency (PI) represents a clear emerging threat. ADMA Biologics' core products, BIVIGAM and ASCENIV, are plasma-derived intravenous immune globulins (IVIG) used for the chronic treatment of PI. Gene therapies, currently in various stages of clinical development and gaining increasing regulatory attention and approvals for certain rare genetic diseases, aim to provide a one-time, potentially curative solution by correcting the underlying genetic defect responsible for the immunodeficiency. Should these gene therapies prove safe, effective, and broadly applicable to a wider range of PI patients, they could significantly reduce or eliminate the long-term need for chronic immunoglobulin replacement therapy, thereby diminishing the market for ADMA's primary product offerings.
AI Analysis | Feedback
ADMA Biologics (ADMA) primarily focuses on specialty plasma-derived biologics, with its main commercial products being intravenous immune globulin (IVIG) therapies, ASCENIV and BIVIGAM, and a hyperimmune globulin product, Nabi-HB. The company is also developing SG-001, a pre-clinical hyperimmune globulin.
Addressable Markets for ADMA Biologics' Main Products:
Intravenous Immune Globulin (IVIG) Market:
- The U.S. intravenous immunoglobulin market was valued at approximately USD 7.27 billion in 2024 and is projected to reach USD 14.42 billion by 2033, demonstrating a Compound Annual Growth Rate (CAGR) of 7.9% from 2024 to 2033. Another estimate places the U.S. IVIG market at USD 4.94 billion in 2025, growing to USD 9.28 billion by 2034, at a CAGR of 7.25%.
- Globally, the intravenous immunoglobulin market was valued at approximately USD 14.32 billion in 2024 and is projected to grow to USD 28.70 billion by 2034, at a CAGR of 7.20% from 2025 to 2034. Another report estimates the global market at USD 17.34 billion in 2025, expected to reach USD 34.92 billion by 2034, with an 8.10% CAGR from 2025 to 2034.
Hyperimmune Globulins Market:
- The global hyperimmune globulins market size was approximately USD 1.94 billion in 2024 and is projected to reach USD 3.56 billion by 2033, growing at a CAGR of 7% from 2025 to 2033. Other estimations value the global market at USD 1.7 billion in 2023, expected to reach USD 3.2 billion by 2033 at a CAGR of 6.2% from 2024 to 2033.
- The U.S. hyperimmune globulins market accounts for approximately 33% of the global demand. Hepatitis B Immunoglobulins, like ADMA's Nabi-HB, represent about 24% of the hyperimmune globulins market.
AI Analysis | Feedback
ADMA Biologics (ADMA) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:
- Growing Demand and Utilization of ASCENIV: The company anticipates continued revenue growth due to strong performance, increased prescriber adoption, and growing patient demand for its lead product, ASCENIV. This product achieved record utilization in recent quarters.
- Yield-Enhancement Production Efficiencies: The FDA's approval of a new production process and yield-enhancement technology is projected to increase finished immunoglobulin (IG) output by 20% or more, using the same amount of starting plasma. This efficiency gain is expected to drive margin expansion and support revenue growth through 2026.
- Expansion of Payer Coverage and Distribution Partnerships: Positive negotiations for 2026 payer coverage and ongoing efforts to onboard additional distribution partners are expected to broaden the reach and improve access for both Bivigam and ASCENIV, thereby accelerating growth.
- New High-Titer Plasma Supply Contracts and Expanded Sourcing: ADMA has secured new high-titer plasma supply contracts and expanded its plasma sourcing. This strengthens the market potential of products like ASCENIV, de-risks the supply chain, and supports long-term revenue growth.
- Potential Launch of Pipeline Product SG-001: Although currently excluded from official revenue guidance, the pipeline product SG-001 represents a significant upside opportunity. If approved, it has the potential to generate substantial high-margin annual revenue, estimated between $300 million and $500 million or more.
AI Analysis | Feedback
Share Repurchases
- ADMA Biologics announced a $500 million share repurchase program in the first quarter of 2025.
- Under this program, approximately $15 million of common stock was repurchased during the second quarter of 2025, with settlements occurring in July 2025.
- The share repurchase program does not have an expiration date.
Share Issuance
- The number of ADMA Biologics' outstanding shares increased by 3.49% in one year.
Capital Expenditures
- ADMA Biologics' latest trailing twelve months (TTM) Capital Expenditure % Average for three years is 14.07%.
- Over the past five years, the company's average Capital Expenditure % Average for three years has been 14.53%.
- A decrease in cash and cash equivalents from $103.1 million at the end of 2024 to $61.4 million as of September 30, 2025, indicates significant investments or expenditures during this period.
Latest Trefis Analyses
| Title | Topic | |
|---|---|---|
| DASHBOARDS | ||
| ADMA Biologics Earnings Notes | ||
| ADMA Biologics Earnings Notes | ||
| Is ADMA Biologics Stock Trading At A Bargain? | Actionable | |
| With ADMA Biologics Stock Surging, Have You Considered The Downside? | Return | |
| ADMA Biologics vs Krystal Biotech: Which Is A Better Investment? | Counter-Intuitive Comparisons | |
| ADMA Biologics (ADMA) Net Income Comparison | Financials | |
| ADMA Biologics (ADMA) Revenue Comparison | Financials | |
| ADMA Biologics (ADMA) Operating Cash Flow Comparison | Financials | |
| ADMA Biologics (ADMA) Tax Expense Comparison | Financials | |
| ADMA Biologics (ADMA) Debt Comparison | Financials |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for ADMA Biologics
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 17.40 |
| Mkt Cap | 4.2 |
| Rev LTM | 812 |
| Op Inc LTM | 167 |
| FCF LTM | 155 |
| FCF 3Y Avg | 32 |
| CFO LTM | 169 |
| CFO 3Y Avg | 45 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 0.1% |
| Rev Chg 3Y Avg | -0.7% |
| Rev Chg Q | 1.0% |
| QoQ Delta Rev Chg LTM | 0.3% |
| Op Mgn LTM | 20.7% |
| Op Mgn 3Y Avg | 21.5% |
| QoQ Delta Op Mgn LTM | 1.4% |
| CFO/Rev LTM | 20.8% |
| CFO/Rev 3Y Avg | 9.6% |
| FCF/Rev LTM | 19.1% |
| FCF/Rev 3Y Avg | 6.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 4.2 |
| P/S | 3.1 |
| P/EBIT | 14.8 |
| P/E | 19.8 |
| P/CFO | 14.2 |
| Total Yield | 6.2% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 0.2% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -7.6% |
| 3M Rtn | 20.2% |
| 6M Rtn | 4.0% |
| 12M Rtn | 4.6% |
| 3Y Rtn | 58.1% |
| 1M Excs Rtn | -11.3% |
| 3M Excs Rtn | 12.4% |
| 6M Excs Rtn | -6.3% |
| 12M Excs Rtn | -12.6% |
| 3Y Excs Rtn | -22.0% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| ADMA BioManufacturing | 250 | 144 | 75 | 37 | 22 |
| Plasma Collection Centers | 8 | 10 | 6 | 5 | 7 |
| License revenue | 0 | ||||
| Corporate | 0 | 0 | 0 | 0 | |
| Total | 258 | 154 | 81 | 42 | 29 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| ADMA BioManufacturing | 247 | 238 | 208 | 141 | 100 |
| Corporate | 48 | 73 | 43 | 54 | 23 |
| Plasma Collection Centers | 35 | 37 | 25 | 13 | 4 |
| Total | 329 | 348 | 276 | 208 | 127 |
Price Behavior
| Market Price | $17.31 | |
| Market Cap ($ Bil) | 4.1 | |
| First Trading Date | 10/17/2013 | |
| Distance from 52W High | -29.4% | |
| 50 Days | 200 Days | |
| DMA Price | $18.09 | $18.10 |
| DMA Trend | indeterminate | up |
| Distance from DMA | -4.3% | -4.4% |
| 3M | 1YR | |
| Volatility | 46.7% | 50.5% |
| Downside Capture | 200.05 | 144.08 |
| Upside Capture | 258.35 | 124.40 |
| Correlation (SPY) | 46.0% | 42.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.97 | 2.46 | 1.74 | 1.51 | 1.13 | 1.24 |
| Up Beta | 0.97 | 1.41 | 1.41 | 1.84 | 1.03 | 0.94 |
| Down Beta | 0.96 | 1.25 | 1.19 | 0.63 | 0.98 | 1.32 |
| Up Capture | 205% | 469% | 304% | 174% | 145% | 457% |
| Bmk +ve Days | 11 | 23 | 37 | 72 | 143 | 431 |
| Stock +ve Days | 9 | 21 | 34 | 62 | 123 | 375 |
| Down Capture | 285% | 232% | 159% | 179% | 123% | 105% |
| Bmk -ve Days | 11 | 18 | 27 | 55 | 108 | 320 |
| Stock -ve Days | 13 | 20 | 30 | 63 | 125 | 358 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| ADMA vs. Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| ADMA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 6.1% | 12.7% | 19.8% | 70.5% | 3.8% | 10.2% | -1.2% |
| Annualized Volatility | 50.3% | 17.3% | 19.3% | 20.0% | 15.3% | 16.7% | 34.5% |
| Sharpe Ratio | 0.28 | 0.53 | 0.81 | 2.56 | 0.04 | 0.41 | 0.06 |
| Correlation With Other Assets | 44.8% | 42.8% | 9.4% | 9.0% | 33.3% | 20.9% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| ADMA vs. Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| ADMA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 51.9% | 7.4% | 14.1% | 19.4% | 11.1% | 6.1% | 20.0% |
| Annualized Volatility | 59.5% | 14.5% | 17.1% | 15.6% | 18.7% | 18.8% | 48.1% |
| Sharpe Ratio | 0.94 | 0.34 | 0.66 | 1.00 | 0.47 | 0.23 | 0.45 |
| Correlation With Other Assets | 28.4% | 34.5% | 9.3% | 5.2% | 28.8% | 14.7% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| ADMA vs. Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| ADMA | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 9.2% | 10.5% | 15.5% | 14.8% | 7.6% | 5.9% | 70.8% |
| Annualized Volatility | 69.1% | 16.6% | 18.0% | 14.8% | 17.6% | 20.8% | 55.7% |
| Sharpe Ratio | 0.43 | 0.52 | 0.75 | 0.83 | 0.35 | 0.25 | 0.91 |
| Correlation With Other Assets | 20.5% | 24.4% | 4.3% | 10.0% | 19.2% | 9.7% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/05/2025 | 10-Q (09/30/2025) |
| 06/30/2025 | 08/06/2025 | 10-Q (06/30/2025) |
| 03/31/2025 | 05/07/2025 | 10-Q (03/31/2025) |
| 12/31/2024 | 03/18/2025 | 10-K (12/31/2024) |
| 09/30/2024 | 11/07/2024 | 10-Q (09/30/2024) |
| 06/30/2024 | 08/08/2024 | 10-Q (06/30/2024) |
| 03/31/2024 | 05/09/2024 | 10-Q (03/31/2024) |
| 12/31/2023 | 02/28/2024 | 10-K (12/31/2023) |
| 09/30/2023 | 11/08/2023 | 10-Q (09/30/2023) |
| 06/30/2023 | 08/09/2023 | 10-Q (06/30/2023) |
| 03/31/2023 | 05/10/2023 | 10-Q (03/31/2023) |
| 12/31/2022 | 03/23/2023 | 10-K (12/31/2022) |
| 09/30/2022 | 11/09/2022 | 10-Q (09/30/2022) |
| 06/30/2022 | 08/10/2022 | 10-Q (06/30/2022) |
| 03/31/2022 | 05/11/2022 | 10-Q (03/31/2022) |
| 12/31/2021 | 03/24/2022 | 10-K (12/31/2021) |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.